Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Long acting cabotegravir for PrEP and new COVID therapies added

Wednesday 02 February 2022

Long acting cabotegravir for use as PrEP (Apretude®) has been added to the list of HIV therapies. Apretude® has been approved by the FDA use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and who have a negative HIV-1 test prior to initiation. The extended-release injectable suspension of cabotegravir can be given as few as six times per year and is initiated with a single 600 mg (3-ml) injection given one month apart for two consecutive months. After the second initiation injection, the recommended continuation injection dose is a single 600 mg (3-ml) injection given every two months.

The comedication list has also been expanded with four key COVID therapies added to the antiviral class of comedications. The new additions are:

  • Molnupiravir (Lagevrio®)
  • Nirmatrelvir/ritonavir (Paxlovid®)
  • Sotrovimab (Xevudy®)
  • Tixagevimab/cilgavimab (Evusheld®)
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016